Last reviewed · How we verify

H5N1 vaccine (Arepanrix) — Competitive Intelligence Brief

H5N1 vaccine (Arepanrix) (H5N1 vaccine (Arepanrix)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: inactivated split-virion influenza vaccine with adjuvant. Area: Immunology.

marketed inactivated split-virion influenza vaccine with adjuvant Immunology Biologic Live · refreshed every 30 min

Target snapshot

H5N1 vaccine (Arepanrix) (H5N1 vaccine (Arepanrix)) — Canadian Immunization Research Network. Arepanrix is an inactivated split-virion H5N1 influenza vaccine that stimulates the immune system to produce antibodies against the H5N1 avian influenza virus.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
H5N1 vaccine (Arepanrix) TARGET H5N1 vaccine (Arepanrix) Canadian Immunization Research Network marketed inactivated split-virion influenza vaccine with adjuvant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (inactivated split-virion influenza vaccine with adjuvant class)

  1. Canadian Immunization Research Network · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). H5N1 vaccine (Arepanrix) — Competitive Intelligence Brief. https://druglandscape.com/ci/h5n1-vaccine-arepanrix. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: